Product code PZF— Pathology

FilmArray Respiratory Panel 2 plus (RP2plus)

Classification name
Mers-Cov And Common Respiratory Pathogens Multiplex Nucleic Acid Detection System
Device class
Class 2
Regulation
21 CFR 866.4001
Advisory panel
Pathology
Total cleared
1
First cleared
Most recent

FDA classification definition

“A Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and common respiratory pathogens multiplex nucleic acid detection system is a qualitative in vitro diagnostic test for the detection and identification of MERS-CoV and common respiratory pathogens – associated nucleic acids in human clinical specimens. The test is indicated for individuals meeting specific MERS-CoV clinical and/or epidemiological criteria. It aids in the differential diagnosis of MERS-CoV infection in conjunction with other clinical, epidemiologic, and laboratory data, in accordance with the guidelines provided by the appropriate public health authorities.”

— U.S. Food and Drug Administration, device classification record for product code PZF under 21 CFR 866.4001, via openFDA

Market context for product code PZF

FDA has cleared 1 device under product code PZF, all in 2017, filed by 1 applicant company. No FDA device recalls reference this product code. Class II devices are moderate-risk and subject to general and special controls; most reach market through 510(k) clearance by demonstrating substantial equivalence to a predicate device.

Top applicants under product code PZF

Recent clearances under product code PZF

Data sourced from openFDA. This site is unofficial and independent of the FDA.